Paul K. Wotton

Dr. Paul K. Wotton is a co-founder and Director at Avenge Bio, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. In addition, he serves as CEO of Obsidian Therapeutics. Dr. Wotton previously served as the Founding President and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He currently serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL), and Cynata Therapeutics (ASX: CYP) as its Chairman, and previously served on the Board of Veloxis Pharmaceuticals A/S prior to its sale to Asahi Kasei.